公开(公告)号：US20160009689A1

公开(公告)日：2016-01-14

申请号：US14772295

申请日：2014-02-27

Applicant: Michael MILLER ,  Kallol BASU ,  Duane DEMONG ,  Jack SCOTT ,  Wei LI ,  Andrew STAMFORD ,  Marc POIRIER ,  Paul TEMPEST ,  MERCK SHARP & DOHME CORP.

Inventor： Michael Miller ,  Kallol Basu ,  Duane DeMong ,  Jack Scott ,  Wei Li ,  Andrew Stamford ,  Marc Poirer ,  Paul Tempest

IPC: C07D403/04 ,  C07D413/14 ,  C07D401/14 ,  C07D471/10 ,  C07D491/107 ,  C07D498/10 ,  C07D487/10 ,  C07D405/14 ,  C07D498/04 ,  C07D487/04 ,  C07D409/14 ,  C07D403/14 ,  C07D498/08

CPC classification number: C07D403/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10

Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

公开(公告)号：US09493440B2

公开(公告)日：2016-11-15

申请号：US14772295

申请日：2014-02-27

Applicant: Merck Sharp & Dohme Corp.

Inventor： Michael Miller ,  Kallol Basu ,  Duane DeMong ,  Jack Scott ,  Wei Li ,  Andrew Stamford ,  Marc Poirer ,  Paul Tempest

IPC: C07D403/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D403/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10

CPC classification number: C07D403/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/107 ,  C07D498/04 ,  C07D498/08 ,  C07D498/10

Abstract: The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.